{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:08:56Z","timestamp":1772168936025,"version":"3.50.1"},"update-to":[{"DOI":"10.12688\/f1000research.53875.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000}}],"reference-count":28,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["PI15\/00886"],"award-info":[{"award-number":["PI15\/00886"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns3:p>\n                    <ns3:bold>Background:<\/ns3:bold>\n                    Although intermittent androgen deprivation therapy was introduced many years ago to improve patients\u2019 quality of life with the same carcinologic efficiency as continuous hormonal therapy, recent data suggest that intermittency could be underutilised. This study aims to estimate the prevalence of prostate cancer patients receiving intermittent androgen deprivation therapy in Spain.\n                  <\/ns3:p>\n                  <ns3:p>\n                    <ns3:bold>Methods:<\/ns3:bold>\n                    A retrospective, longitudinal study was conducted using electronic drug dispensation data from four Spanish autonomous communities, which encompass 17.23 million inhabitants (36.22% of the total population in Spain). We estimated intermittent androgen therapy use (%IAD) and the prevalence of patients under intermittent androgen therapy in reference to the total number of PC patients using hormonal therapy (P\n                    <ns3:sub>IAD<\/ns3:sub>\n                    ) and stratified by region. Other outcome variables included the pharmaceutical forms dispensed and the total direct annual expenditure on androgen deprivation therapy\u2010associated medications.\n                  <\/ns3:p>\n                  <ns3:p>\n                    <ns3:bold>Results:<\/ns3:bold>\n                    A total of 863,005 dispensations corresponding to a total of 65,752 men were identified, treated with either luteinizing hormone-releasing hormone (LHRH) analogues (353,162) administered alone or in combination with anti\u2010androgens (509,843). Overall, the mean (\u00b1SD) age of the patients was 76.9 (\u00b110.4) years. Results revealed that the mean annual P\n                    <ns3:sub>IAD<\/ns3:sub>\n                    along the study was 6.6% in the total population studied, and the overall %IAD during the five\u2010year study period was 5.6%. The mean cost of hormonal therapy per year was 25 million euros for LHRH analogues and 6.3 million euros for anti-androgens.\n                  <\/ns3:p>\n                  <ns3:p>\n                    <ns3:bold>Conclusions:<\/ns3:bold>\n                    \u00a0Few prostate cancer patients in Spain use the intermittent androgen deprivation therapy suggesting underutilization of a perfectly valid option for a significant proportion of patients, missing the opportunity to improve their quality of life and to reduce costs for the National Health Service with comparable overall survival rates than continuous therapy.\n                  <\/ns3:p>","DOI":"10.12688\/f1000research.53875.2","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T09:40:08Z","timestamp":1650534008000},"page":"1069","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence study of intermittent hormonal therapy of Prostate Cancer patients in Spain"],"prefix":"10.12688","volume":"10","author":[{"given":"Xavier","family":"Bonfill-Cosp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0364-4827","authenticated-orcid":false,"given":"Ariadna","family":"Auladell-Rispau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignasi","family":"Gich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Carlos","family":"Saiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Ignacio","family":"Pijoan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0498-6033","authenticated-orcid":false,"given":"Iratxe","family":"Urreta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3167-2315","authenticated-orcid":false,"given":"Jos\u00e9 Antonio","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"9-13","DOI":"10.1038\/bjc.2012.523","article-title":"Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?","volume":"108","author":"L Bourke","year":"2013","journal-title":"Br. J. Cancer."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"187-192","DOI":"10.1038\/aja.2011.102","article-title":"Hematological changes during androgen deprivation therapy.","volume":"14","author":"M Grossmann","year":"2012","journal-title":"Asian J. Androl."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"704-709","DOI":"10.1016\/j.eururo.2013.02.002","article-title":"Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.","volume":"65","author":"C Jespersen","year":"2014","journal-title":"Eur. Urol."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"825-836","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them.","volume":"67","author":"P Nguyen","year":"2015","journal-title":"Eur. Urol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e457-e465","DOI":"10.3747\/co.21.1865","article-title":"Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events.","volume":"21","author":"M Krahn","year":"2014","journal-title":"Curr. Oncol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"139-146","DOI":"10.1016\/0960-0760(96)00018-0","article-title":"Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.","volume":"58","author":"N Sato","year":"1996","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"144-151","DOI":"10.23736\/S0393-2249.17.03066-1","article-title":"Hormonal treatment and quality of life of prostate cancer patients: new evidence.","volume":"70","author":"M Tucci","year":"2018","journal-title":"Minerva Urol. Nefrol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1038\/bjc.2013.211","article-title":"Reply: Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?","volume":"108","author":"D Rosario","year":"2013 May 28","journal-title":"Br. J. Cancer."},{"key":"ref9","first-page":"2275-2282","article-title":"Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma.","volume":"50","author":"N Bruchovsky","year":"1990","journal-title":"Cancer Res."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"720-727","DOI":"10.1016\/j.eururo.2015.10.007","article-title":"Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).","volume":"69","author":"C Schulman","year":"2016","journal-title":"Eur. Urol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1314-1325","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer.","volume":"368","author":"M Hussain","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"895-903","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy [published correction appears in N Engl J Med. 2012 Dec 6;367(23):2262].","volume":"367","author":"J Crook","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"373-378","DOI":"10.1007\/s12094-016-1538-5","article-title":"Intermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy: a phase 3 GICOR study.","volume":"19","author":"F Casas","year":"2017","journal-title":"Clin. Transl. Oncol."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1269-1277","DOI":"10.1016\/j.eururo.2009.02.016","article-title":"Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.","volume":"55","author":"F Calais da Silva","year":"2009","journal-title":"Eur. Urol."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1261-1269","DOI":"10.1001\/jamaoncol.2015.2895","article-title":"Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.","volume":"1","author":"S Magnan","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref16","article-title":"EAU Guidelines 2019.","author":"N Mottet"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"9-26","DOI":"10.1111\/bju.14809","article-title":"Guidance - Prostate cancer: diagnosis and management: \u00a9 NICE (2019) Prostate cancer: diagnosis and management.","volume":"124","year":"2019","journal-title":"BJU Int."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"620-623","DOI":"10.6004\/jnccn.2018.0036","article-title":"NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection.","volume":"16","author":"P Carroll","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"796-803","DOI":"10.1002\/pds.4744","article-title":"Population-based estimate of the use of intermittent androgen deprivation therapy in prostate cancer patients in Catalonia, Spain.","volume":"28","author":"J Cordero","year":"2019","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"865-871","DOI":"10.1097\/COC.0000000000000763","article-title":"Population-based Assessment of Intermittent Androgen Deprivation Therapy Utilization for Relapsed, Nonmetastatic, Hormone-sensitive Adenocarcinoma of the Prostate.","volume":"43","author":"B Janzen","year":"2020","journal-title":"Am. J. Clin. Oncol."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"53-61","DOI":"10.1016\/j.urolonc.2019.01.021","article-title":"Impact of androgen deprivation therapy on mood, cognition, and risk for AD.","volume":"38","author":"M Cherrier","year":"2020","journal-title":"Urol. Oncol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1251-1257","DOI":"10.1016\/j.juro.2016.12.022","article-title":"Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study.","volume":"197","author":"H Tsai","year":"2017","journal-title":"J. Urol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"773-776","DOI":"10.6004\/jnccn.2014.0187","article-title":"New developments in the treatment of castration-resistant prostate cancer.","volume":"12","author":"C Higano","year":"2014","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e000040","DOI":"10.1136\/esmoopen-2016-000040","article-title":"Editorial on an international survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries.","volume":"1","author":"A Liede","year":"2016 cited 2021 Jan 31","journal-title":"Ann Oncol."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"3240-3248","DOI":"10.1002\/cam4.3895","article-title":"Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous\/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial.","volume":"10","author":"A Yokomizo","year":"2021 May cited 2021 May 3","journal-title":"Cancer Med."},{"key":"ref26","article-title":"Bolet\u00edn Oficial del Estado (BOE) 2012."},{"key":"ref27","article-title":"Bolet\u00edn de Coyuntura del Mercado del Medicamento en Espa\u00f1a. No 113."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"139-140","DOI":"10.1016\/j.aprim.2013.01.006","article-title":"\u00abImpacta el uso de las TICS en el gasto farmac\u00e9utico? Incorporaci\u00f3n de la receta electr\u00f3nica\u00bb [Impact of the use of ICT on pharmacy costs. The incorporation of the electronic prescription].","volume":"45","author":"O Acezat","year":"2013","journal-title":"Aten. Primaria."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/10-1069\/v2\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/10-1069\/v2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/10-1069\/v2\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T09:45:27Z","timestamp":1666863927000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/10-1069\/v2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":28,"URL":"https:\/\/doi.org\/10.12688\/f1000research.53875.2","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.131327.r135442","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.131327.r135442","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,21]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/10-1069\/v2#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.57300.r97868, Helena Colom Codina, Department of Pharmacy and Pharmaceutical technology and Physical-Chemistry, Faculty of Pharmacy and Food sciences, University of Barcelona, Barcelona, Spain, 06 Dec 2021, version 1, 1 approved, 1 approved with reservations","URL":"https:\/\/f1000research.com\/articles\/10-1069\/v1#referee-response-97868","order":0,"name":"referee-response-97868","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>Jos&eacute; Antonio Cordero Rigol<\/b>; \n<i>Posted: 13 Apr 2022<\/i>; Thanks Dr. Colom for your comments and support.  As for your suggestion &quot;\n<i>To complete the results I would suggest to perform statistical comparisons of the prevalence values \u200b\u200bbetween communities and between the years of follow-up.<\/i>&quot; Agree. The statistical comparison will be added to the version 2 but very significant differences (p&lt;0.001) among communities and years of follow-up will be expected due to the big size of the sample analysed. We therefore concentrated on comparing the magnitude of the differences summarised in table 2.  With respect to your comment that &quot;\n<i>I would have appreciated some discussion about the reasons why the prevalence of IAD in Spain is low<\/i>&quot;. Agree. This result is quite surprising and we only have conjectures to explain that e.g., Liede \n<i>at al.<\/i> reported important differences in IAD use among European countries due to &quot;clinicians devise individualised treatment courses of optimal length based on patient characteristics while accounting for associated risks and benefits of ADT. This individualised clinical approach is represented in the variation of survey responses as it can become difficult to compartmentalise patients when deciding on treatment strategies.&quot; The fact that in Spain we have 4 physicians\/1000 inhabitants may explain some extra healthcare pressure than in France, Italy or UK with &gt;4.5 physicians\/1000 inhabitants. In any case, the data are fairly consistent when it comes to demonstrating this weak use of IAD therapy in Spain.","URL":"https:\/\/f1000research.com\/articles\/10-1069\/v2#referee-comment-8092","order":1,"name":"referee-comment-8092","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.131327.r135442, Philipp Dahm, Department of Urology, Minneapolis VAMC, University of Minnesota, Minneapolis, MN, USA, 27 Oct 2022, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/10-1069\/v2#referee-response-135442","order":2,"name":"referee-response-135442","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This work was supported by Instituto de Salud Carlos III under the project number PI15\/00886 (co\u2010funded by the European Regional Development Fund\/European Social Fund, \u201cInvesting in your future\u201d). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}